Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4048390, 12 pages
http://dx.doi.org/10.1155/2016/4048390
Review Article

New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity

1Center for Metabolic Function Regulation, Department of Microbiology, School of Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
2Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
3Department of Oriental Medical Physiology, College of Korean Medicine, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
4PAEAN Biotechnology, 160 Tachno-2 Street, Yuseong-gu, Daejeon 305-500, Republic of Korea

Received 22 October 2015; Accepted 9 December 2015

Academic Editor: Jeremiah R. Brown

Copyright © 2016 Gi-Su Oh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Rosenberg, L. Van Camp, and T. Krigas, “Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode,” Nature, vol. 205, no. 4972, pp. 698–699, 1965. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Cohen and S. J. Lippard, “Cisplatin: from DNA damage to cancer chemotherapy,” Progress in Nucleic Acid Research and Molecular Biology, vol. 67, pp. 93–130, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Arany and R. L. Safirstein, “Cisplatin nephrotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” Kidney International, vol. 73, no. 9, pp. 994–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of cisplatin nephrotoxicity,” Toxins, vol. 2, no. 11, pp. 2490–2518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. H. Hanigan and P. Devarajan, “Cisplatin nephrotoxicity: molecular mechanisms,” Cancer Therapy, vol. 1, pp. 47–61, 2003. View at Google Scholar
  9. Y. Ido, “Pyridine nucleotide redox abnormalities in diabetes,” Antioxidants & Redox Signaling, vol. 9, no. 7, pp. 931–942, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. H.-J. Kim, G.-S. Oh, A. Shen et al., “Augmentation of NAD+ by NQO1 attenuates cisplatin-mediated hearing impairment,” Cell Death and Disease, vol. 5, no. 6, Article ID e1292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. G.-S. Oh, H.-J. Kim, J.-H. Choi et al., “Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice,” Kidney International, vol. 85, no. 3, pp. 547–560, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Braidy, G. J. Guillemin, H. Mansour, T. Chan-Ling, A. Poljak, and R. Grant, “Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats,” PLoS ONE, vol. 6, no. 4, Article ID e19194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Massudi, R. Grant, N. Braidy, J. Guest, B. Farnsworth, and G. J. Guillemin, “Age-associated changes in oxidative stress and NAD+ metabolism in human tissue,” PLoS ONE, vol. 7, no. 7, Article ID e42357, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H.-J. Kim, G.-S. Oh, S.-K. Choe, T. H. Kwak, R. Park, and H.-S. So, “NAD+ metabolism in age-related hearing loss,” Aging and Disease, vol. 5, no. 2, pp. 150–159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Chen, J. Bruno, E. Easlon et al., “Tissue-specific regulation of SIRT1 by calorie restriction,” Genes and Development, vol. 22, no. 13, pp. 1753–1757, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Adam-Vizi and L. Tretter, “The role of mitochondrial dehydrogenases in the generation of oxidative stress,” Neurochemistry International, vol. 62, no. 5, pp. 757–763, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. P. Murphy, “How mitochondria produce reactive oxygen species,” The Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Werner, M. J. Costa, L. G. Mitchell, and R. Nayar, “Nephrotoxicity of xenobiotics,” Clinica Chimica Acta, vol. 237, no. 1-2, pp. 107–154, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Pabla, R. F. Murphy, K. Liu, and Z. Dong, “The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity,” American Journal of Physiology—Renal Physiology, vol. 296, no. 3, pp. F505–F511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Ciarimboli, “Membrane transporters as mediators of cisplatin side-effects,” Anticancer Research, vol. 34, no. 1, pp. 547–550, 2014. View at Google Scholar · View at Scopus
  21. D. M. Townsend, K. D. Tew, L. He, J. B. King, and M. H. Hanigan, “Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity,” Biomedicine and Pharmacotherapy, vol. 63, no. 2, pp. 79–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. D. Wainford, R. J. Weaver, K. N. Stewart, P. Brown, and G. M. Hawksworth, “Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway,” Toxicology, vol. 249, no. 2-3, pp. 184–193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. A. G. Santos, C. S. Catão, N. M. Martins, C. Curti, M. L. P. Bianchi, and A. C. Santos, “Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria,” Archives of Toxicology, vol. 81, no. 7, pp. 495–504, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Çetin, E. Devrim, B. Kilicoglu, A. Avci, Ö. Çandir, and I. Durak, “Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods,” Journal of Applied Toxicology, vol. 26, no. 1, pp. 42–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. H. Szeto, “Mitochondria-targeted peptide antioxidants: novel neuroprotective agents,” The AAPS Journal, vol. 8, no. 3, pp. E521–E531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. E. Berry and J. M. Hare, “Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications,” Journal of Physiology, vol. 555, no. 3, pp. 589–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Gottlieb, “Cytochrome P450: major player in reperfusion injury,” Archives of Biochemistry and Biophysics, vol. 420, no. 2, pp. 262–267, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Miller, G. J. Dusting, C. L. Roulston, and C. G. Sobey, “NADPH-oxidase activity is elevated in penumbral and non-ischemic cerebral arteries following stroke,” Brain Research, vol. 1111, no. 1, pp. 111–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Liu and R. Baliga, “Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis,” Kidney International, vol. 63, no. 5, pp. 1687–1696, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Bai and A. I. Cederbaum, “Mitochondrial catalase and oxidative injury,” Biological Signals and Receptors, vol. 10, no. 3-4, pp. 189–199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Geiszt, “NADPH oxidases: new kids on the block,” Cardiovascular Research, vol. 71, no. 2, pp. 289–299, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. T. Quinn, M. C. B. Ammons, and F. R. DeLeo, “The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction,” Clinical Science, vol. 111, no. 1, pp. 1–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Bánfi, B. Malgrange, J. Knisz, K. Steger, M. Dubois-Dauphin, and K.-H. Krause, “NOX3, a superoxide-generating NADPH oxidase of the inner ear,” The Journal of Biological Chemistry, vol. 279, no. 44, pp. 46065–46072, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. H.-J. Kim, J.-H. Lee, S.-J. Kim et al., “Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity,” Journal of Neuroscience, vol. 30, no. 11, pp. 3933–3946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Ramesh and W. B. Reeves, “Inflammatory cytokines in acute renal failure,” Kidney International Supplement, vol. 66, no. 91, pp. S56–S61, 2004. View at Google Scholar · View at Scopus
  36. C. Y. Lu, J. Hartono, M. Senitko, and J. Chen, “The inflammatory response to ischemic acute kidney injury: a result of the ‘right stuff’ in the ‘wrong place’?” Current Opinion in Nephrology and Hypertension, vol. 16, no. 2, pp. 83–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Ramesh and W. Brian Reeves, “TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity,” The Journal of Clinical Investigation, vol. 110, no. 6, pp. 835–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Ramesh, B. Zhang, S. Uematsu, S. Akira, and W. B. Reeves, “Endotoxin and cisplatin synergistically induce renal dysfunction and cytokine production in mice,” American Journal of Physiology—Renal Physiology, vol. 293, no. 1, pp. F325–F332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Zhang, G. Ramesh, C. C. Norbury, and W. B. Reeves, “Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells,” Kidney International, vol. 72, no. 1, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Dong and S. S. Atherton, “Tumor necrosis factor-α in cisplatin nephrotoxicity: a homebred foe?” Kidney International, vol. 72, no. 1, pp. 5–7, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Ramesh and W. B. Reeves, “TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure,” American Journal of Physiology—Renal Physiology, vol. 285, no. 4, pp. F610–F618, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. P. D. Sánchez-González, F. J. López-Hernández, J. M. López-Novoa, and A. I. Morales, “An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity,” Critical Reviews in Toxicology, vol. 41, no. 10, pp. 803–821, 2011. View at Publisher · View at Google Scholar
  43. K. Tsuruya, T. Ninomiya, M. Tokumoto et al., “Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death,” Kidney International, vol. 63, no. 1, pp. 72–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Abraham, “Nuclear factor-κB and its role in sepsis-associated organ failure,” Journal of Infectious Diseases, vol. 187, supplement 2, pp. S364–S369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Ramesh and W. B. Reeves, “p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice,” American Journal of Physiology—Renal Physiology, vol. 289, no. 1, pp. F166–F174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Yamakawa, S. Eguchi, T. Matsumoto et al., “Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-κB and p38 mitogen-activated protein kinase on tumor necrosis factor-α production,” Endocrinology, vol. 140, no. 8, pp. 3562–3572, 1999. View at Google Scholar · View at Scopus
  47. R. Medzhitov and C. A. Janeway Jr., “Decoding the patterns of self and nonself by the innate immune system,” Science, vol. 296, no. 5566, pp. 298–300, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Kono and K. L. Rock, “How dying cells alert the immune system to danger,” Nature Reviews Immunology, vol. 8, no. 4, pp. 279–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. D. U. Ferreiro and E. A. Komives, “Molecular mechanisms of system control of NF-κB signaling by IκBα,” Biochemistry, vol. 49, no. 8, pp. 1560–1567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Zhang, G. Ramesh, S. Uematsu, S. Akira, and W. B. Reeves, “TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity,” Journal of the American Society of Nephrology, vol. 19, no. 5, pp. 923–932, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Ramesh, S. R. Kimball, L. S. Jefferson, and W. B. Reeves, “Endotoxin and cisplatin synergistically stimulate TNF-α production by renal epithelial cells,” American Journal of Physiology—Renal Physiology, vol. 292, no. 2, pp. F812–F819, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. A. F. McGettrick and L. A. J. O'Neill, “The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction,” Molecular Immunology, vol. 41, no. 6-7, pp. 577–582, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Tsung, J. R. Klune, X. Zhang et al., “HMGB1 release induced by liver ischemia involves Toll-like receptor 4–dependent reactive oxygen species production and calcium-mediated signaling,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 2913–2923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. R. H. Houtkooper, C. Cantó, R. J. Wanders, and J. Auwerx, “The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways,” Endocrine Reviews, vol. 31, no. 2, pp. 194–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. C. A. Elvehjem, R. J. Madden, F. M. Strong, and D. W. Wolley, “The isolation and identification of the anti-black tongue factor. 1937,” The Journal of Biological Chemistry, vol. 277, no. 34, article e22, 2002. View at Google Scholar · View at Scopus
  56. W. Ying, “NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences,” Antioxidants & Redox Signaling, vol. 10, no. 2, pp. 179–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Belenky, K. L. Bogan, and C. Brenner, “NAD+ metabolism in health and disease,” Trends in Biochemical Sciences, vol. 32, no. 1, pp. 12–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Dali-Youcef, M. Lagouge, S. Froelich, C. Koehl, K. Schoonjans, and J. Auwerx, “Sirtuins: the ‘magnificent seven’, function, metabolism and longevity,” Annals of Medicine, vol. 39, no. 5, pp. 335–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Michishita, J. Y. Park, J. M. Burneskis, J. C. Barrett, and I. Horikawa, “Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins,” Molecular Biology of the Cell, vol. 16, no. 10, pp. 4623–4635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. B. J. North, B. L. Marshall, M. T. Borra, J. M. Denu, and E. Verdin, “The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase,” Molecular Cell, vol. 11, no. 2, pp. 437–444, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Vaziri, S. K. Dessain, E. Ng Eaton et al., “hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase,” Cell, vol. 107, pp. 149–159, 2001. View at Google Scholar
  62. M. C. Haigis, R. Mostoslavsky, K. M. Haigis et al., “SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells,” Cell, vol. 126, no. 5, pp. 941–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Liszt, E. Ford, M. Kurtev, and L. Guarente, “Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase,” The Journal of Biological Chemistry, vol. 280, no. 22, pp. 21313–21320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Imai, F. B. Johnson, R. A. Marciniak, M. McVey, P. U. Park, and L. Guarante, “Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 65, pp. 297–302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Hasegawa, S. Wakino, K. Yoshioka et al., “Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 51–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. K. Hasegawa, S. Wakino, K. Yoshioka et al., “Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function,” The Journal of Biological Chemistry, vol. 285, no. 17, pp. 13045–13056, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. D. H. Kim, Y. J. Jung, J. E. Lee et al., “Sirt1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53,” American Journal of Physiology—Renal Physiology, vol. 301, no. 2, pp. F427–F435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Neumann and M. Naumann, “Beyond IκBs: alternative regulation of NF-κB activity,” The FASEB Journal, vol. 21, no. 11, pp. 2642–2654, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., “Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,” The EMBO Journal, vol. 23, no. 12, pp. 2369–2380, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Yoshizaki, J. C. Milne, T. Imamura et al., “SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes,” Molecular and Cellular Biology, vol. 29, no. 5, pp. 1363–1374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. J. Levine and M. Oren, “The first 30 years of p53: growing ever more complex,” Nature Reviews Cancer, vol. 9, no. 10, pp. 749–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. J.-P. Kruse and W. Gu, “Modes of p53 regulation,” Cell, vol. 137, no. 4, pp. 609–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Tang, W. Zhao, Y. Chen, Y. Zhao, and W. Gu, “Acetylation is indispensable for p53 activation,” Cell, vol. 133, no. 4, pp. 612–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. C. L. Brooks and W. Gu, “The impact of acetylation and deacetylation on the p53 pathway,” Protein and Cell, vol. 2, no. 6, pp. 456–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Li, M. Banck, S. Mujtaba, M.-M. Zhou, M. M. Sugrue, and M. J. Walsh, “p53-Induced growth arrest is regulated by the mitochondrial SirT3 deacetylase,” PLoS ONE, vol. 5, no. 5, Article ID e10486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. W. Gu and R. G. Roeder, “Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain,” Cell, vol. 90, no. 4, pp. 595–606, 1997. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Zhao, S. Lu, L. Wu et al., “Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1,” Molecular and Cellular Biology, vol. 26, no. 7, pp. 2782–2790, 2006. View at Publisher · View at Google Scholar
  78. A. Kotsinas, V. Aggarwal, E.-J. Tan, B. Levy, and V. G. Gorgoulis, “PIG3: a novel link between oxidative stress and DNA damage response in cancer,” Cancer Letters, vol. 327, no. 1-2, pp. 97–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. J. D. Amaral, J. M. Xavier, C. J. Steer, and C. M. P. Rodrigues, “Targeting the p53 pathway of apoptosis,” Current Pharmaceutical Design, vol. 16, no. 22, pp. 2493–2503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. V. Vaseva and U. M. Moll, “The mitochondrial p53 pathway,” Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1787, no. 5, pp. 414–420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Mouchiroud, R. H. Houtkooper, and J. Auwerx, “NAD+ metabolism: a therapeutic target for age-related metabolic disease,” Critical Reviews in Biochemistry and Molecular Biology, vol. 48, no. 4, pp. 397–408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Krishnakumar and W. L. Kraus, “The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets,” Molecular Cell, vol. 39, no. 1, pp. 8–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Thomas and A. V. Tulin, “Poly-ADP-ribose polymerase: machinery for nuclear processes,” Molecular Aspects of Medicine, vol. 34, no. 6, pp. 1124–1137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. P. M. Goodwin, P. J. Lewis, M. I. Davies, C. J. Skidmore, and S. Shall, “The effect of gamma radiation and neocarzinostatin of NAD and ATP levels in mouse leukaemia cells,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 543, no. 4, pp. 576–582, 1978. View at Publisher · View at Google Scholar · View at Scopus
  85. C. J. Skidmore, M. I. Davies, P. M. Goodwin et al., “The involvement of poly(ADP-ribose) polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea,” European Journal of Biochemistry, vol. 101, no. 1, pp. 135–142, 1979. View at Google Scholar · View at Scopus
  86. C. Cantó and J. Auwerx, “NAD+ as a signaling molecule modulating metabolism,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 76, pp. 291–298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Launay-Vacher, J.-B. Rey, C. Isnard-Bagnis, G. Deray, and M. Daouphars, “Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 6, pp. 903–909, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Losonczy, C. Máthé, V. Müller, K. Szondy, and J. Moldvay, “Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer,” Magyar Onkologia, vol. 54, no. 4, pp. 289–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Araki, Y. Sasaki, and J. Milbrandt, “Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration,” Science, vol. 305, no. 5686, pp. 1010–1013, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. W. Ying, G. Wei, D. Wang et al., “Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia,” Frontiers in Bioscience, vol. 12, no. 7, pp. 2728–2734, 2007. View at Google Scholar · View at Scopus
  91. V. B. Pillai, N. R. Sundaresan, G. Kim et al., “Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway,” The Journal of Biological Chemistry, vol. 285, no. 5, pp. 3133–3144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. P. Bai, C. Cantó, H. Oudart et al., “PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation,” Cell Metabolism, vol. 13, no. 4, pp. 461–468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. I. A. Ayoub, E. Jian Lee, C. S. Ogilvy, M. F. Beal, and K. I. Maynard, “Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats,” Neuroscience Letters, vol. 259, no. 1, pp. 21–24, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. I. A. Ayoub and K. I. Maynard, “Therapeutic window for nicotinamide following transient focal cerebral ischemia,” NeuroReport, vol. 13, no. 2, pp. 213–216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. K. L. Brewer and J. S. Hardin, “Neuroprotective effects of nicotinamide after experimental spinal cord injury,” Academic Emergency Medicine, vol. 11, no. 2, pp. 125–130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Kaneko, J. Wang, M. Kaneko et al., “Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models,” Journal of Neuroscience, vol. 26, no. 38, pp. 9794–9804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. A. A. Sauve, “NAD+ and vitamin B3: from metabolism to therapies,” The Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 883–893, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. W. Ying, P. Garnier, and R. A. Swanson, “NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes,” Biochemical and Biophysical Research Communications, vol. 308, no. 4, pp. 809–813, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Ying, C. C. Alano, P. Garnier, and R. A. Swanson, “NAD+ as a metabolic link between DNA damage and cell death,” Journal of Neuroscience Research, vol. 79, no. 1-2, pp. 216–223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Gaikwad, D. J. Long II, J. L. Stringer, and A. K. Jaiswal, “In vivo role of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue,” The Journal of Biological Chemistry, vol. 276, pp. 22559–22564, 2001. View at Publisher · View at Google Scholar
  101. D. Ross, J. K. Kepa, S. L. Winski, H. D. Beall, A. Anwar, and D. Siegel, “NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms,” Chemico-Biological Interactions, vol. 129, no. 1-2, pp. 77–97, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Gao, A. Singh, K. Macri et al., “Antioxidant components of naturally-occurring oils exhibit marked anti-inflammatory activity in epithelial cells of the human upper respiratory system,” Respiratory Research, vol. 12, article 92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. D. K. Gessner, R. Ringseis, M. Siebers et al., “Inhibition of the pro-inflammatory NF-κB pathway by a grape seed and grape marc meal extract in intestinal epithelial cells,” Journal of Animal Physiology and Animal Nutrition, vol. 96, no. 6, pp. 1074–1083, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Pazdro and J. R. Burgess, “The antioxidant 3H-1,2-dithiole-3-thione potentiates advanced glycation end-product-induced oxidative stress in SH-SY5Y cells,” Experimental Diabetes Research, vol. 2012, Article ID 137607, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. C. I. Jones III, H. Zhu, S. F. Martin, Z. Han, Y. Li, and B. R. Alevriadou, “Regulation of antioxidants and phase 2 enzymes by shear-induced reactive oxygen species in endothelial cells,” Annals of Biomedical Engineering, vol. 35, no. 5, pp. 683–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. O. Moscovitz, P. Tsvetkov, N. Hazan et al., “A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1,” Molecular Cell, vol. 47, no. 1, pp. 76–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. R. H. Haefeli, M. Erb, A. C. Gemperli et al., “NQo1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels,” PLoS ONE, vol. 6, no. 3, Article ID e17963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. X. Huang, Y. Dong, E. A. Bey et al., “An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis,” Cancer Research, vol. 72, no. 12, pp. 3038–3047, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. A. B. Pardee, Y. Z. Li, and C. J. Li, “Cancer therapy with β-lapachone,” Current Cancer Drug Targets, vol. 2, no. 3, pp. 227–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. L. S. Li, E. A. Bey, Y. Dong et al., “Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy,” Clinical Cancer Research, vol. 17, no. 2, pp. 275–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. S. M. Planchon, S. Wuerzberger, B. Frydman et al., “β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response,” Cancer Research, vol. 55, no. 17, pp. 3706–3711, 1995. View at Google Scholar · View at Scopus
  112. J. H. Hwang, D. W. Kim, E. J. Jo et al., “Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice,” Diabetes, vol. 58, no. 4, pp. 965–974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. Y.-H. Kim, J. H. Hwang, J.-R. Noh et al., “Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity,” Cardiovascular Research, vol. 91, no. 3, pp. 519–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. S.-Y. Kim, N. H. Jeoung, C. J. Oh et al., “Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation,” Circulation Research, vol. 104, no. 7, pp. 842–850, 2009. View at Publisher · View at Google Scholar · View at Scopus